Background and objectives X-linked Alport syndrome is caused by mutations in the COL4A5 gene. Although many COL4A5 mutations have been detected, the mutation detection rate has been unsatisfactory. Some men with X-linked Alport syndrome show a relatively mild phenotype, but molecular basis investigations have rarely been conducted to clarify the underlying mechanism.
Introduction
Alport syndrome is a hereditary disorder of type IV collagen that progresses to CKD and usually develops into ESRD. Symptoms include sensorineural hearing loss and ocular abnormalities. X-linked Alport syndrome (XLAS) accounts for approximately 85% of patients with Alport syndrome. These patients have mutations in the COL4A5 gene, which encodes the type IV collagen-a5 [a5(IV)] chain. COL4A5 mutations result in abnormal a5(IV) expression, with a typically complete absence of a5(IV) in the glomerular basement membrane (GBM) and Bowman's capsule in men and a mosaic expression pattern in women (1) .
To date, .500 different COL4A5 mutations have been identified in patients with XLAS, but mutation detection rates vary widely, ranging between approximately 40%-82% (2-6). The low detection rate is unsatisfactory, because it hampers a deeper understanding of the genotypephenotype relationship in patients with XLAS. Previous studies have reported that missense and in-frame mutations have milder phenotypes compared with truncating mutations (7) (8) (9) . However, these studies did not fully consider the effect of splice site mutations on COL4A5 expression. This study requires careful analysis of COL4A5 transcripts and assessment of intronic mutations, which have been increasingly identified as a cause of aberrant splicing for various disorders, including Alport syndrome (10) (11) (12) .
Recently, we reported that 29% of patients with XLAS showed a5(IV) expression on kidney glomeruli, and these patients displayed milder phenotypes (13) . All of these patients positive for a5(IV) had nontruncating mutations, including in-frame deletions or in-frame mutations resulting from splice site mutations and exon skipping. This finding suggests that patients with XLAS with in-frame mutations can show a milder phenotype, even when derived from a splice site mutation (13) . Therefore, it is important to clarify splice site mutations as either in-frame or out-of-frame mutations after examining transcripts to estimate the phenotype.
It is well known among clinical nephrologists that some men with XLAS show a relatively mild phenotype, leading to the development of ESRD after the age of 60 years old. The reason for the mild phenotype has been attributed to missense or in-frame mutations or somatic mosaicism (8, 9, 13, 14) . One of our patients showed a novel mechanism leading to a mild phenotype revealed by transcript analysis extracted from the kidney. These patients showed both normal and abnormal spliced transcripts, and the normal transcript prevented progression to the typically severe phenotype of XLAS.
In this study, we report on 11 patients showing aberrant splicing of primary transcripts, providing additional insight into genotype-phenotype correlations in XLAS.
Materials and Methods

Ethical Considerations
All procedures were reviewed and approved by the Institutional Review Board of Kobe University School of Medicine. Informed consent was obtained from patients or their parents.
Inclusion Criteria
Clinical and laboratory findings of Japanese patients with XLAS were obtained from their medical records. Patients were referred to our hospital for clinical evaluation or genetic analysis. Most patients were followed in various local hospitals in Japan. DNA and data sheets were sent to our laboratory after acceptance of the request for mutational analysis. We routinely conduct genetic analysis of clinically diagnosed patients with XLAS. When we detect mutations that may possibly affect RNA processing, we routinely analyze transcripts to confirm the mutation-induced splicing abnormalities. When we fail to detect mutations in typical patients with XLAS using DNA-based mutation assays, we conduct transcript analyses as well. All patients with splice site mutations that led to an atypical splicing pattern were included in this study.
One hundred fifty-two patients were genetically diagnosed with XLAS at our laboratory; 22 patients had splice site mutations, and 11 of them showed atypical splicing patterns. These 11 patients were included in this study.
The degree of urinary protein excretion was evaluated using the urinary protein-to-creatinine ratio. eGFR was calculated using the Schwartz equation for patients #17 years old (15, 16) and GFR-estimating equations for Japanese for patients $18 years old (17) . Images of kidney a5(IV) staining were sent to us for evaluation of the staining patterns and assessed by the same person (K.N.). eGFR was measured on the basis of the data on data sheets.
Mutational Analyses
Mutational analyses of COL4A5 were carried out using the following methods. (1) PCR and direct sequencing of genomic DNA of all exons and exon-intron boundaries were performed. (2) When we detected a suspected splicing site mutation or failed to detect mutations with step 1 analysis, RT-PCR of mRNA and direct sequencing of abnormal mRNA products were carried out.
Genomic DNA was isolated from peripheral blood leukocytes from patients using the Quick Gene Mini 80 System (Fujifilm Corporation, Tokyo, Japan) according to the manufacturer's instructions. For genomic DNA analysis, all 51 specific exons of COL4A5 were amplified by PCR as described previously (5) . PCR-amplified products were then purified and subjected to direct sequencing using a Dye Terminator Cycle Sequencing Kit (Amersham Biosciences, Piscataway, NJ) with an automatic DNA sequencer (ABI Prism 3130; Perkin Elmer Applied Biosystems, Foster City, CA). Total RNA was extracted from blood leukocytes, kidneys, and/or hair roots. RNA from leukocytes was isolated using a Paxgene Blood RNA Kit (Qiagen Inc., Chatsworth, CA) and then reverse transcribed into cDNA using random hexamers and a Superscript III Kit (Invitrogen, Carlsbad, CA). RNA from kidneys and hair roots was isolated as described previously (14) . cDNA was amplified by nested PCR using primer pairs for COL4A5 as described previously with slight modifications (sequences available on request) (18) . PCR-amplified products were purified and subjected to direct sequencing.
Immunohistochemical Analyses
Immunohistochemical analyses were performed using frozen sections of kidney tissue. The immunohistochemical procedure has been described previously (19) (20) (21) . A mixture of fluorescein isothiocyanate-conjugated rat mAb for the human a5(IV) chain (H53) and Texas red-conjugated rat mAb for the human a2(IV) chain (H25) was purchased from Shigei Medical Research Institute (Okayama, Japan). The epitopes were EAIQP at positions 675-679 of the a2(IV) chain and IDVEF at positions 251-255 of the a5(IV) chain.
Results
Patients' Clinical Features and Pathologic Findings
In total, 11 patients were included in the study. Mutations creating or eliminating the 39 splice site consensus sequences were detected in six patients (patient IDs 7, 17, 27, 28, 128, and 158), including two patients who had relatively deep intron mutations (patient IDs 128 and 158 with mutation of intervening sequence (IVS)27-18 and IVS29-8, respectively). One patient had a mutation at the last nucleotide of exon 41, altering the 59 splice site consensus (patient ID 21). These patients proceeded to transcript analysis to determine the influence of the mutations on splicing. Detection of mutations in another four patients failed with genomic DNA-based assays, prompting transcript analyses that detected intronic exonization in patient IDs 19, 48, 126, and 217. All mutations together with patients' clinical, laboratory, and pathologic data are shown in Table 1 . All patients showed typical clinical features of XLAS.
Acceptor Splice Site Mutations
Six patients had mutations at 39 splice sites ( Figure 1 , A-F). Four of them had mutations in the last intron dinucleotides (patient IDs 7, 17, 27, and 28) that did not result in skipping of complete exonic sequences but produced new 39 splice sites downstream of authentic sites, creating small deletions in COL4A5 mRNA (19, 1, 1, and 18 bp, respectively) (Figure 1, A-D) . One patient had an IVS27-18a.g RT-PCR results showed both normal and abnormal transcripts only in cDNA extracted from the kidney, and this case showed an extremely mild phenotype for a man with X-linked Alport syndrome with a truncating mutation.
mutation, which resulted in exon 27 skipping (patient ID 128) ( Figure 1E ). The IVS29-8t.a mutation (patient ID 158) produced a new splice acceptor site, resulting in a 6-bp insertion in the mature transcript ( Figure 1F ).
Donor Splice Site Mutation
One patient had a single nucleotide substitution at the last position of exon 41 ( Figure 1G ). Although the mutation is a missense change (p.G1263S), cDNA analysis revealed skipping of exon 41 (186 bp). This finding is consistent with previous studies pointing to a substantial fraction of missense mutations that alter pre-mRNA processing (22) .
Deep Intronic Mutations
A failure to detect mutations using genomic DNA analysis in four patients with typical features of XLAS (patient IDs 19, 48, 126, and 217) prompted us to conduct transcript analyses. RT-PCR showed insertions of cryptic exonic sequences in each case (Figure 1 , H-K, Supplemental Figure 1 ). We then conducted genomic DNA analysis of intronic sequences and found point mutations that produced new splice sites (Figure 1, H-K) . Interestingly, patient ID 19 showed a milder phenotype than a typical patient with XLAS with a truncating mutation. This patient had both normal and abnormal transcripts of the kidney that led to his phenotype being milder than that usually seen with a man with XLAS with a truncating mutation. Patient ID 217 had a mutation at position +5 of the new exon ( Figure 1K ). All cryptic exons had stop codons in them and thus, turned out to be truncating mutations (Supplemental Figure 1) . From these results, we could group these four patients as having truncating mutations.
Discussion
This study provides the first case series report on aberrant splice site mutations. We identified six splice consensus sequence mutations, including two relatively deeper intronic nucleotide substitutions, one exonic mutation, and four deep intron mutations.
It is well established that genotype-phenotype shows a strong correlation in XLAS (7-9). Jais et al. (9) reported that large deletions and nonsense mutations confer a 90% probability of ESRD by the age of 30 years old compared with a 70% risk with splice site mutations and a 50% risk with missense mutations. Gross et al. Recently, we reported that 29% of men with XLAS were positive for a5(IV) on the GBM and showed significantly milder phenotypes, including milder proteinuria, later onset of ESRD, and less occurrence of hearing loss (13) . All of the a5(IV)-positive group had nontruncating mutations, including three deletion mutations (9, 36, and 384 bp) and one splice site mutation, which led to exon 9 (81 bp) skipping. From these results, it was suggested that inframe mutations could show a milder phenotype, even if derived from a splice site mutation (13) . One patient (patient ID 128) in this study had a 105-bp deletion (full exon 27 skipping) and showed an extremely mild phenotype for a man with XLAS. He is now 46 years old and has not developed ESRD (eGFR=41 ml/min per 1.73 m 2 ).
One man (patient ID 19) showed an atypically mild phenotype of slight proteinuria with normal renal function at the age of 22 years old. The intron mutation in this patient created a cryptic exon that included a stop codon, creating a truncating mutation. Patients with truncating mutations usually show a severe disease course. Bekhernia et al. (7) reported that patients with truncating mutations develop to ESRD at an average age of 25 years old, and Gross et al. (8) reported that patients with nonsense or other large mutations develop to ESRD at an average age of 19.8 years old. To clarify the reason why our patient showed a milder phenotype while possessing a truncating mutation, we conducted additional transcript analysis using cDNA extracted from the kidney and hair roots. Interestingly, cDNA from the kidney showed both a larger-sized band and a normal-sized band on electrophoresis and confirmed the presence of normal transcripts lacking the cryptic exon. This finding suggests that this patient's intronic exonization does not occur completely in the kidney and that some transcript escaped from producing the cryptic exon. This result could explain why this patient shows a milder phenotype of XLAS.
Patient ID 217 had a mutation at IVS cryptic exon position +5T.G that produced a cryptic splice donor site. The IVS+5G position is susceptible to aberrant splice site activation, and this point mutation of G to another nucleotide always changes the splice site, usually showing exon skipping (23) . However, this patient created a cryptic splice site with the IVS+5T.G mutation and produced the cryptic splice site. This kind of mutation has been rarely reported (23) .
In a recently published study, we reported that some men with XLAS were positive for a5(IV) at the GBM and that all were diagnosed with XLAS using a genetic approach (13) . However, four patients in this study who showed no mutations using standard genome DNA direct sequencing analysis (patients ID 19, 48, 126, and 217) had abnormal a5(IV) expression, and we proceeded to transcript analysis and detected aberrant splicing in a deep intron. From these results, it is suggested that the genetic approach and immunohistochemical analysis provide some clues as to diagnosis of XLAS for patients with atypical a5(IV) expression and patients with an absence of any mutation by standard direct sequencing, respectively.
A recent case study reported a high sensitivity for detecting somatic mosaic mutations in the COL4A5 gene using nextgeneration sequencing (24) . High-throughput sequencing technologies may not only lower the cost of DNA ID 128. IVS27-18A .G potentially sequencing but also help identify those low-percentage somatic mosaic mutations, which may help increase the mutation detection rates for XLAS as well as transcript analysis.
The results of this study may have implications in future therapeutic trials of XLAS. In muscular dystrophies, clinical trials using antisense oligonucleotides to induce exon skipping of specific mutations or drugs developed to allow read through of nonsense mutations are ongoing and have the aim of changing truncating mutations into nontruncating mutations (25) . Similar therapeutic strategies may be available for patients with genetically diagnosed XLAS in the future, and accurate descriptions of the transcriptomic consequences of somatic or germ-line DNA changes in relevant tissues should be a prerequisite for inclusion in any clinical trials.
In conclusion, we report 10 intronic mutations and one exonic mutation that produce aberrant splicing, including four deep intronic mutations that produced cryptic exons.
One patient showed a milder phenotype, although he had a truncating mutation because of different splicing patterns in different tissues. With transcript analysis, we can determine splice site mutations as either truncating or nontruncating mutations. This study provides valuable data, which will help with future analysis of genotype-phenotype correlations, because only transcript analysis makes it possible to divide splice site mutations into two groups of either truncating or nontruncating mutations. This report also illustrates that the low mutation detection rate in XLAS can be improved by thorough transcript analysis and highlights the importance of distinct tissue-specific exon inclusion levels that may explain the severity of genetic diseases in general. 
